Dabigatran patent expiry?

Dabigatran (brand: Pradaxa) is a prescription anticoagulant. Whether you’re asking about patent expiry in general or the expected loss of exclusivity in a specific country, the dates vary a lot by jurisdiction.

Quick high-level timeline (global)

• Dabigatran etexilate (the original drug) protection began in the early 2000s, with multiple patent families and different expiry dates.
• In the EU/UK, the practical “go-to-generic” timing for dabigatran was generally around the mid-to-late 2010s, but branded supply/exclusivity and patent thickets can delay actual launches.
• In the US, exclusivity/patent protection also delayed generics until the late 2010s for certain forms/doses.

To give you the exact expiry date(s)

Please tell me:

1. Country/region (US, EU/UK, Canada, etc.)
2. Which product (dabigatran etexilate capsules; specific strengths like 75/110/150 mg)
3. Whether you want first generic entry, patent expiry, or loss of exclusivity (marketing exclusivity)

If you share the region (e.g., “EU” or “US”), I can give the most relevant expiry date(s) and what they’re based on.